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TREATMENT
THERAPEUTIC GOAL(S)
● Provide supportive therapy until gas-
trointestinal (GI) tract returns to normal.
● Remove underlying cause if known.
ACUTE GENERAL TREATMENT
● Nothing by mouth (NPO) for 12 to 48
hours.
● Frequent small quantities of oral fluids
may be offered if vomiting is infrequent.
● Subcutaneous crystalloids may be used
for animals with mild dehydration
deficits.
● Intravenous fluids are required if patient
is moderately or severely dehydrated or
has any evidence of hypovolemia.
● After vomiting has ceased for 12 hours,
offer small amounts of water or ice
cubes.
● Initial diet should be easily digestible
starch, low protein, and low fat (such as
rice with cottage cheese or boiled
chicken).
● Acid blockers (H2 blockers: famotidine
[0.5 mg/kg PO, IV, or SC q 24h], raniti-
dine [0.5–2 mg/kg PO or SC q 12h],
cimetidine [10 mg/kg PO, IV, or SC q
6–8h]): indicated if hematemesis or
melena is present.
● Antiemetics: usually not necessary,
metoclopramide (0.2–0.4 mg/kg SC q
8–12h) or phenothiazine (0.1–0.5 mg/
kg SC q 8–24h) derivatives (chlorpro-
mazine, prochlorperazine) are good
first choices if needed.
● Protectants/adsorbants:bismuth subsal-
icylate (1 ml/4 kg PO up to q 4–6h),
kaolin-pectin, activated charcoal and
aluminum-, magnesium-, or barium-con-
taining products are often used for
coating GI mucosa and binding bacte-
ria and their toxins.
● Anticholinergics (e.g., atropine, pro-
pantheline) are not recommended.
● Antibiotics are not indicated unless there
is evidence of a bacterial cause or breech
of GI mucosal integrity (hematemesis or
melena).
DRUG INTERACTIONS
● High-dose phenothiazine derivative
antiemetics (e.g., chlorpromazine, prochl-
orperazine) can cause or exacerbate
hypotension, especially in dehydrated or
hypovolemic patients.
● Bismuth subsalicylate should be used
cautiously, especially in cats, due to gen-
eration of salicylate (aspirin) in intestine.
● Bismuth subsalicylate will normally
cause stool to turn black in color,
which can be mistaken for melena.
RECOMMENDED MONITORING
● Vital parameters.
● Frequency, volume, and character of
diarrhea and vomiting.
PROGNOSIS AND 
OUTCOME
Prognosis is excellent, usually resolves 24
to 48 hours after onset of signs.
PEARLS & 
CONSIDERATIONS
COMMENTS
● If vomiting is not frequent, foregoing
antiemetics allows better assessment of
response to supportive therapy. If no
response occurs within 1 to 2 days,other
differentials should be investigated.
● Animals with marked dehydration or
hypovolemia at presentation should
have more detailed diagnostic evalua-
tion; acute nonspecific gastroenteritis
rarely produces severe systemic signs.
SUGGESTED READING
Webb C, Twedt DC: Canine gastritis. Vet Clin
North Am Small Anim Pract 33(5):969–985,
v–vi, 2003.
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BASIC INFORMATION
DEFINITION
Gastrointestinal (GI) endocrine disease
occurs as a result of a tumor of one or
more hormone-secreting cells in the GI
tract. Insulin-secreting β-cell tumors are
discussed elsewhere (p XXX).
SYNONYM(S)
General:amine precursor uptake and decar-
boxylation (APUD) tumors; APUDoma
Specific: gastrinoma (Zollinger-Ellison
syndrome), VIPoma (Verner-Morrison
syndrome)
EPIDEMIOLOGY
SPECIES, AGE, SEX
● Gastrinoma: rare; middle-aged to old
dogs and cats.
● Glucagonoma: rare; middle-aged to old
dogs; not reported in cats.
● Carcinoid syndrome: rare; middle-aged
to old dogs and cats.
ASSOCIATED CONDITIONS AND DIS-
ORDERS: Necrolytic migratory erythema
and diabetes mellitus (glucagonoma).
CLINICAL PRESENTATION
DISEASE FORMS/SUBTYPES
● Gastrinoma: gastrin
● Glucagonoma: glucagon
● Carcinoid syndrome: serotonin
● Somatostatinomas*: somatostatin
● Pancreatic polypeptide-oma*: pancre-
atic polypeptide
● VIPoma*: vasoactive intestinal poly-
peptide
HISTORY, CHIEF COMPLAINT
● Gastrinoma: vomiting, weight loss,
anorexia , diarrhea.
● Glucagonoma: ulcerative dermatitis, diar-
rhea, lethargy, weight loss, inappetance,
possible polyuria and polydipsia.
● Carcinoid syndrome: often no overt
clinical signs; possible abdominal pain,
vomiting, weight loss, anorexia.
PHYSICAL EXAM FINDINGS
● Gastrinoma: weight loss; lethargy;
abdominal pain, pale mucous mem-
branes, melena, and/or collapse and
shock as a result of GI ulceration.
● Glucagonoma: ulcerative dermatitis,
lethargy.
● Carcinoid syndrome: no specific find-
ings; possible anorexia, weight loss,
acute abdomen due to obstruction.
ETIOLOGY AND
PATHOPHYSIOLOGY
● Specialized endocrine cells that secrete
peptides are found throughout the GI
tract.
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● Neoplasia of these cells results in
excess secretion of the hormone(s).
● Clinical signs occur as a result of the
specific hormone oversecretion.
DIAGNOSIS
DIFFERENTIAL
DIAGNOSIS
See vomiting (p XXX),weight loss (p XXX),
anorexia/inappetance (p XXX), diarrhea
(p XXX), acute abdomen (p XXX), ulcera-
tive dermatitis (p XXX), hepatocutaneous
syndrome? (p XXX).
INITIAL DATABASE
● The diagnosis is made based on appro-
priate clinical signs and immunohisto-
chemical staining of the tumor
● A complete blood count, serum bio-
chemical profile, and urinalysis should
be evaluated to help rule out other
diagnoses.
● Mild hyperglycemia, increased liver
enzymes, hypoalbuminemia, and pos-
sible glucosuria may be seen with
glucagonoma.
● A regenerative or iron-deficiency ane-
mia, possible leukocytosis, hypopro-
teinemia,and increased liver enzymes
may be seen with gastrinoma.
● Results are usually normal with car-
cinoid syndrome.
● Radiographs and ultrasound results are
usually normal but may help identify the
primary tumor or metastatic lesions.
ADVANCED OR CONFIRMATORY
TESTING
● Glucagonoma: Increased plasma glu-
cagon concentrations (in the absence of
other diseases causing hyperglucagone-
mia), histopathology of skin lesions,
and hypoaminoacidemia are supportive.
Results of liver function tests are normal
(versus abnormal function with hepato-
cutaneous syndrome).
● Gastrinoma: Increased fasting serum
gastrin concentration (in the absence
of other diseases causing hypergas-
trinemia) and gastric hyperacidity; GI
ulceration and/or increased gastric
rugal folds seen with endoscopy or
contrast radiography; and excessive
response to a gastrin-secretagogue
(secretin or calcium) are supportive.
● Carcinoid syndrome: Increased sero-
tonin metabolites (5-hydroxyindole-
acetic acid) in urine are supportive.
● Confirmation requires immunohisto-
chemical staining of the tumor.
TREATMENT
THERAPEUTIC GOAL(S)
● Removal of tumor.
● Management of associated clinical
signs.
ACUTE GENERAL TREATMENT
● Fluid and electrolyte abnormalities
should be corrected if present.
● Gastrinoma: treat hyperacidity and GI
ulceration (see Gastric Ulcer, p XXX).
● Surgical removal of the primary tumor
and any visible metastasis, if possible.
With gastrinoma, ulcer excision may
also be needed.
● If the pancreas is manipulated during
surgery, treat postoperatively for pan-
creatitis (see Pancreatitis, p XXX).
CHRONIC TREATMENT
● Because of the high incidence of metas-
tasis at the time of diagnosis, surgery is
not often curative and subsequent med-
ical management is needed.
● Gastrinoma: treat hyperacidity and GI
ulcerations (see above); somatostatin
analog treatment (octreotide: 2 µg/kg
SQ q 12h up to 10–20 µg/kg subcuta-
neously [SQ] q 8h) can be tried.
● Glucagonoma: amino acid supplemen-
tation (eggs, prescription diets, possible
IV amino acid infusion) has been sug-
gested but is unproven; manage skin
lesions (see Hepatocutaneous Syndrome,
p XXX, Ulcerative Dermatitis, p XXX);
octreotide (6 µg/kg SQ q 8h ) can be
tried.
● Effective chemotherapy for these
tumors has not been reported in the
dog and cat.
POSSIBLE COMPLICATIONS
The most common postoperative compli-
cation is pancreatitis in dogs.
RECOMMENDED MONITORING
Monitor recurrence of clinical signs.
PROGNOSIS AND 
OUTCOME
● Glucagonoma: poor if concurrent
advanced liver disease (mean 5 months)
or metastasis.
● Gastrinoma: poor long-term prognosis
because metastasis present in 70%
of cases at time of diagnosis (mean
8 months).
● Carcinoid syndrome: Many are asympto-
matic and are found postmortem.
Prognosis is guarded if metastatic disease
is present.
PEARLS & 
CONSIDERATIONS
COMMENTS
These are complex tumors and very diffi-
cult to diagnose; referral to a specialist
center is advised.
SUGGESTED READING
Feldman EC, Nelson RW: Gastrinoma, glucag-
onoma, and other APUDomas. In Felman
EC, Nelson RW (eds): Canine and Feline
Endocrinology and Reproduction, ed 3.
Philadelphia,WB Saunders,2004,pp 645–658.
Johnson SE: Pancreatic APUDomas. Semin Vet
Med Surg Small Anim Pract 4:202–211,
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